拨康视云启动招股，瞄准眼科治疗领域创新高地

Core Viewpoint - Cloudbreak Pharma Inc. has launched its IPO, focusing on innovative treatments for ophthalmic diseases, with significant backing from over 20 renowned investment institutions, raising over HKD 1.1 billion in previous funding rounds [1][4]. Group 1: Product Pipeline and Market Potential - The company has developed a pipeline of innovative drug candidates targeting major ophthalmic diseases, with core products CBT-001 and CBT-009 showing substantial market potential [2][5]. - CBT-001 aims to prevent the progression of pterygium and reduce conjunctival congestion, filling a gap in the market as there are currently no approved drugs for this condition, with a projected global market size reaching USD 178.3 million by 2028 and USD 1.79 billion by 2033, reflecting a compound annual growth rate of 58.6% [5][6]. - CBT-009 targets myopia in adolescents, utilizing a non-aqueous formulation that enhances patient tolerance, safety, and product stability, addressing a growing need due to increased screen time and academic pressure [5][6]. Group 2: Research and Development Commitment - The company emphasizes R&D, with annual expenditures projected to grow from USD 15.3 million in 2022 to USD 37.9 million in 2024, supporting the development of proprietary technology platforms for treating both anterior and posterior eye diseases [7]. - Cloudbreak Pharma has two clinical-stage candidates and four preclinical candidates addressing mainstream eye diseases such as dry eye syndrome, glaucoma, and presbyopia, enhancing its appeal to investors [6][7]. Group 3: Strategic Growth and Internationalization - The IPO is expected to provide strong momentum for the company to expand its R&D capabilities, accelerate product pipeline advancement, and promote international strategic initiatives in the growing ophthalmic biotech sector [7].